Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

20.46
+0.85004.33%
Post-market: 20.580.1200+0.59%18:25 EST
Volume:1.23M
Turnover:24.80M
Market Cap:996.04M
PE:-6.41
High:20.82
Open:19.10
Low:18.68
Close:19.61
52wk High:30.00
52wk Low:3.42
Shares:48.68M
Float Shares:36.78M
Volume Ratio:0.74
T/O Rate:3.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1901
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-32.10%
PB:-9.44
PE(LYR):-6.41

Loading ...

Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Yesterday

UroGen Pharma Grants Inducement RSUs Covering Up to 51,200 Shares

Reuters
·
Yesterday

UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile

Simply Wall St.
·
Mar 05

Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

TIPRANKS
·
Mar 03

Stock Track | UroGen Pharma Soars 7.78% After-Hours on Improved Earnings, Revenue Growth and Favorable Loan Refinancing

Stock Track
·
Mar 03

UroGen Falls on 4Q Results Miss, Debt Refinancing

Dow Jones
·
Mar 03

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 02

Stock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss

Stock Track
·
Mar 02

Urogen Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

UroGen Pharma Q4 revenue misses; forecasts FY operating expenses $240 mln-$250 mln

Reuters
·
Mar 02

Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss

MT Newswires Live
·
Mar 02

UroGen FY 2025 revenue USD 109.8 million up 21%

Reuters
·
Mar 02

UroGen Pharma Q4 EPS $(0.54) Misses $(0.53) Estimate, Sales $37.837M Miss $39.922M Estimate

Benzinga
·
Mar 02

UroGen Pharma Refinances Term Loan With Pharmakon Advisors at $250 Million Facility

Reuters
·
Mar 02

UroGen reports durable ZUSDURI complete responses across EORTC risk groups in ENVISION trial analysis

Reuters
·
Feb 27

UroGen Pharma Ltd. Updates Financial Calendar

Reuters
·
Feb 23

Urogen Pharma General Counsel Jason Drew Smith Disposes of Common Shares

Reuters
·
Feb 12

Urogen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares

Reuters
·
Feb 05

Guggenheim Sticks to Its Buy Rating for Urogen Pharma (URGN)

TIPRANKS
·
Feb 02

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 23